Article

Regulation of endothelial cell activation and angiogenesis by injectable peptide nanofibers

School of Energy, Environmental, Biological, and Medical Engineering, University of Cincinnati, Cincinnati, OH 45221, USA.
Acta biomaterialia (Impact Factor: 5.68). 09/2011; 8(1):154-64. DOI: 10.1016/j.actbio.2011.08.029
Source: PubMed

ABSTRACT RAD16-II peptide nanofibers are promising for vascular tissue engineering and were shown to enhance angiogenesis in vitro and in vivo, although the mechanism remains unknown. We hypothesized that the pro-angiogenic effect of RAD16-II results from low-affinity integrin-dependent interactions of microvascular endothelial cells (MVECs) with RAD motifs. Mouse MVECs were cultured on RAD16-II with or without integrin and MAPK/ERK pathway inhibitors, and angiogenic responses were quantified. The results were validated in vivo using a mouse diabetic wound healing model with impaired neovascularization. RAD16-II stimulated spontaneous capillary morphogenesis, and increased β(3) integrin phosphorylation and VEGF expression in MVECs. These responses were abrogated in the presence of β(3) and MAPK/ERK pathway inhibitors or on the control peptide without RAD motifs. Wide-spectrum integrin inhibitor echistatin completely abolished RAD16-II-mediated capillary morphogenesis in vitro and neovascularization and VEGF expression in the wound in vivo. The addition of the RGD motif to RAD16-II did not change nanofiber architecture or mechanical properties, but resulted in significant decrease in capillary morphogenesis. Overall, these results suggest that low-affinity non-specific interactions between cells and RAD motifs can trigger angiogenic responses via phosphorylation of β(3) integrin and MAPK/ERK pathway, indicating that low-affinity sequences can be used to functionalize biocompatible materials for the regulation of cell migration and angiogenesis, thus expanding the current pool of available motifs that can be used for such functionalization. Incorporation of RAD or similar motifs into protein engineered or hybrid peptide scaffolds may represent a novel strategy for vascular tissue engineering and will further enhance design opportunities for new scaffold materials.

0 Followers
 · 
188 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The effect of chronic hyperglycemic exposure on endothelial cell (EC) phenotype, impaired wound neovascularization, and healing is not completely understood. The hypotheses are: 1) chronic exposure to diabetic conditions in vivo impairs the angiogenic potential of ECs and 2) this deficiency can be improved by an extracellular microenvironment of angiogenic peptide nanofibers. Approach: Angiogenic potential of microvascular ECs isolated from diabetic (db/db) and wild type (wt) mice was assessed by quantifying migration, proliferation, apoptosis, capillary morphogenesis, and vascular endothelial growth factor (VEGF) expression for cell cultures on Matrigel (Millipore, Billerica, MA) or nanofibers under normoglycemic conditions. The in vivo effects of nanofiber treatment on wound vascularization were determined using two mouse models of diabetic wound healing. Results: Diabetic ECs showed significant impairments in migration, VEGF expression, and capillary morphogenesis. The nanofiber microenvironment restored capillary morphogenesis and VEGF expression and significantly increased proliferation and decreased cell apoptosis of diabetic cells versus wt controls. In diabetic wounds, nanofibers significantly enhanced EC infiltration, neovascularization, and VEGF protein levels, as compared to saline treatment; this effect was observed even in MMP9 knockout mice with endothelial progenitor cell (EPC) deficiency. Innovation: The results suggest a novel approach for correcting diabetes-induced endothelial deficiencies via cell interactions with a nanofiber-based provisional matrix in the absence of external angiogenic stimuli. Conclusion: Impaired endothelial angiogenic potential can be restored by angiogenic cell stimulation in the nanofiber microenvironment; this suggests that nanofiber technology for diabetic wound healing and treatment of other diabetes-induced vascular deficiencies is promising.
    11/2014; 3(11):717-728. DOI:10.1089/wound.2013.0511
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article presents a review of recent advances in the employment of nanofibrous scaffolds in the developing field of tissue engineering. To begin with, we take a glance into various methods of fabrication of nanofibers relevant to tissue engineering. Focus will also be given to the issues that influence the selection of materials for the synthesis of the nanofibrous scaffolds. The article will also acquaint the reader with various aspects of nanofiber fabrication and characterization that hold significance in tissue regeneration including control of factors like nanofiber porosity, fiber alignment, cell infiltration and degradation of the fibers. Incorporation of bioactive factors into the nanofibrous scaffolds with specific relevance to tissue engineering shall be discussed. Finally, a systematic overview of applications and work done in case of nanofibers till date in tissue regeneration technology encompassing bone, cartilage, ligament/tendons, skin, corneal, cardiovascular neural and other tissues will be presented. The article will conclude with a brief discussion of challenges that need to be overcome and prospective directions for amendment in the fabrication and design of the nanofibrous scaffolds.
    08/2014; 4(8). DOI:10.1166/jbt.2014.1214
  • [Show abstract] [Hide abstract]
    ABSTRACT: A catechol containing peptide derivative was designed and synthesized that could form a conjugate with the anti-cancer drug of bortezomib (BTZ) through the complex interaction between boronic acid and catechol moieties, resulting in a supramolecular hydrogel. The hydrogel could sustainably release BTZ through boronate ester hydrolysis, which suggested its potential for topical administration to release BTZ and inhibit tumor growth.
    RSC Advances 09/2014; 4(91). DOI:10.1039/C4RA08011D · 3.71 Impact Factor